{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:38:29Z","timestamp":1768012709311,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014389","name":"Amarin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014389","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jchf.2020.06.019","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T16:09:36Z","timestamp":1599667776000},"page":"859-866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Angiotensin-Neprilysin Inhibition in Black Americans"],"prefix":"10.1016","volume":"8","author":[{"given":"Cecilia","family":"Berardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillary S.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol I.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrence X.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hrishikesh","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Velazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam D.","family":"DeVore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2020.06.019_bib1","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1161\/CIR.0000000000000534","article-title":"Cardiovascular health in African Americans: a scientific statement from the American Heart Association","volume":"136","author":"Carnethon","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2020.06.019_bib2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.cardfail.2015.05.013","article-title":"Heart failure in non-Caucasians, women, and older adults: a white paper on special populations from the Heart\u00a0Failure Society of America Guideline Committee","volume":"21","author":"Colvin","year":"2015","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2020.06.019_bib3","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.168.19.2138","article-title":"Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis","volume":"168","author":"Bahrami","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jchf.2020.06.019_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/CIRCULATIONAHA.117.027551","article-title":"Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005-2014): ARIC study community surveillance","volume":"138","author":"Chang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2020.06.019_bib5","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa0807265","article-title":"Racial differences in incident heart failure among young adults","volume":"360","author":"Bibbins-Domingo","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2020.06.019_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1071-9164(99)90001-5","article-title":"Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group","volume":"5","author":"Carson","year":"1999","journal-title":"J\u00a0Card Fail"},{"issue":"18","key":"10.1016\/j.jchf.2020.06.019_bib7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM200105033441802","article-title":"Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared\u00a0with white patients with left ventricular dysfunction","volume":"344","author":"Exner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2020.06.019_bib8","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(03)00262-6","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials","volume":"41","author":"Shekelle","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2020.06.019_bib9","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/HYPERTENSIONAHA.108.110270","article-title":"Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors","volume":"51","author":"Miller","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2020.06.019_bib10","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2020.06.019_bib11","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2020.06.019_bib12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2018.01.004","article-title":"Rationale and design of the Comparison of Sacubitril\/Valsartan Versus Enalapril on Effect on NT-pro-BNP in Patients Stabilized From an Acute Heart\u00a0Failure Episode (PIONEER-HF) trial","volume":"198","author":"Velazquez","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2020.06.019_bib13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2020.06.019_bib14","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","article-title":"Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril\/valsartan or enalapril in the PIONEER-HF trial","volume":"139","author":"Morrow","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2020.06.019_bib15","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2020.06.019_bib16","first-page":"513","article-title":"Racial differences in natriuretic peptide levels: the Dallas Heart Study","volume":"3","author":"Gupta","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2020.06.019_bib17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.amjcard.2017.06.030","article-title":"Differences in natriuretic peptide levels by race\/ethnicity (from the Multi-Ethnic Study of Atherosclerosis)","volume":"120","author":"Gupta","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2020.06.019_bib18","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/CIRCRESAHA.119.315026","article-title":"Race, natriuretic peptides, and high-carbohydrate challenge: a clinical trial","volume":"125","author":"Patel","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jchf.2020.06.019_bib19","first-page":"43","article-title":"Comparative effectiveness of sacubitril-valsartan versus ACE\/ARB therapy in heart failure with reduced ejection fraction","volume":"8","author":"Tan","year":"2020","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2020.06.019_bib20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijcard.2018.03.121","article-title":"Angioedema in heart failure patients treated with sacubitril\/valsartan (LCZ696) or enalapril in the PARADIGM-HF study","volume":"264","author":"Shi","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2020.06.019_bib21","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/01.CIR.0000144310.04433.BE","article-title":"N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients","volume":"110","author":"Bettencourt","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2020.06.019_bib22","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jacc.2009.06.041","volume":"54","author":"Cleland","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2020.06.019_bib23","first-page":"148","article-title":"Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis","volume":"2","author":"Savarese","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177920304522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177920304522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:55:46Z","timestamp":1761972946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177920304522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S2213177920304522"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2020.06.019","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin-Neprilysin Inhibition in Black Americans","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2020.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}